Abstract
This annex describes the copper in biosystems, namely copper proteins and copper interactions with biomolecules and human diseases. Copper transport and metabolic diseases can be diagnosed or followed up in the future using CuCl2 radiopharmaceutical in human clinical trials. Although most of the copper proteins covered in this annex are important and active in non‑human biological systems, the significant role of copper in organisms can also be investigated by the application of the 64Cu radionuclide for basic biological and biochemical research.
| Original language | English |
|---|---|
| Title of host publication | Copper-64 Radiopharmaceuticals; Production, Quality Control and Clinical Applications |
| Publisher | International Atomic Energy Agency |
| Publication date | 2022 |
| Pages | 98-110 |
| Chapter | Annex II |
| ISBN (Print) | 978–92–0–129621–4 |
| ISBN (Electronic) | 978–92–0–129421–0 |
| Publication status | Published - 2022 |
| Series | IAEA Radioisotopes and Radiopharmaceuticals Series |
|---|---|
| Number | 7 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Copper biology'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver